- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06049667
A Phase 1 Clinical Trail of NTQ2494 Tablets in Patients With Advanced Hematological Malignancies
A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics and Preliminary Efficacy of NTQ2494 Tablets in Patients With Advanced Hematological Malignancies
NTQ2494 tablet, an anti-tumor molecular targeted drug, is an AXL kinase inhibitor.
The objectives were to evaluate the safety and tolerability, PK characteristics and preliminary efficacy of NTQ2494 tablets in patients with advanced hematological malignancies.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Yu meng Zhou
- Phone Number: 86-025-85109999
- Email: yumeng_zhou@163.com
Study Locations
-
-
Tianjin
-
Tianjin, Tianjin, China, 300000
- Recruiting
- Hematology Hospital of the Chinese Academy of Medical Sciences
-
Principal Investigator:
- Jianxiang Wang
-
Contact:
- jianxiang wang
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- ≥18 years in age, male or female.
- Relapsed/refractory AML patients.
- ECOG performance status score is 0 to 2.
- Life expectancy of at least 3 months.
- Adequate bone marrow and good organ function.
- Ability to understand the purpose and risks of the study and the willingness to sign a written informed consent document.
Exclusion Criteria:
- Receiving anticancer therapy including immunotherapy, targeted therapy, endocrine therapy, radiotherapy and chemotherapy within 2 weeks or 5 half-lives (whichever is longer) prior to starting study treatment.
- Receiving any other investigational agents within 4 weeks prior to starting study treatment.
- Having major surgery within 4 weeks prior to starting study treatment, or intended to undergo surgery during the trail.
- AML with any of the following: 1) acute promyelocytic leukemia; 2) AML with blast crisis of chronic myelogenous leukemia; 3) central nervous system leukemia.
- Prior or current other malignancy (except cured noninvasive basal cell or squamous cell skin cancer and/or other cured carcinoma in situ; except for other malignancies that have achieved clinical cure for > 5 years and have not recurred within 5 years).History of severe cardiovascular or cerebrovascular disease.
- Use of strong inhibitors or strong inducers of CYP3A4 or P-gp within 7 days prior to starting study treatment.
- Receiving (attenuated) live vaccines within 4 weeks prior to starting study treatment and/or planning to receive (attenuated) live vaccines during the trial.
- With unresolved clinically significant non-hematological toxicities from prior AML therapy (chemotherapy, targeted therapy, immunotherapy, radiotherapy and surgery), defined as any grade 2 or higher grade (CTCAE v5.0), alopecia and other events that are tolerable as judged by the investigator.
- Patients who have received previous allogeneic hematopoietic stem cell transplantation; or received autologous hematopoietic stem cell transplantation within 3 months prior to starting study treatment.
- Unable to swallow oral tablets, or other conditions seriously affecting gastrointestinal absorption judged by the investigator.
- Patients with uncontrolled infections unsuitable for the trail judged by the investigator.
- Known infection with hepatitis B, hepatitis C, HIV or Syphilis.
- Known alcohol or drug dependence.
- Patients with mental disorders or poor compliance.
- Patients with a previous history of severe allergy to any drug or food.
- Lactating or pregnant female, and females or males (or partners) who plan to pregnant and do not agree to use adequate contraception for the duration of the trail and up to 3 months after completion of the last study treatment.
- Other reasons judged by the investigator that the patients unsuitable for the trail.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: NTQ2494
For each dose level, multiple doses of NTQ2494 tablets will be administered as 28-day treatment (per cycle).
|
Drug: NTQ2494 tablet Part 1: Dose escalation, single and multiple doses of NTQ2494 with dose modifications based on tolerability criteria. For each dose level, a single dose of NTQ2494 tablets will be first administered orally, then continuous 28-day treatment will start (per cycle). Part 2: Dose expansion, recommended doses from Part 1. For each dose level, multiple doses of NTQ2494 tablets will be administered as 28-day treatment (per cycle). |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum tolerance dose (MTD) and dose limiting toxicity (DLT)
Time Frame: 30 days
|
MTD is defined as the maximum dose level at which no more than 1 of 3 participants experience a DLT within the days of single dose and the first 28 days of multiple doses in dose escalation part.
|
30 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cmax of single dose
Time Frame: At the end of Cycle 1 (each cycle is 28 days)
|
At the end of Cycle 1 (each cycle is 28 days)
|
|
AUC0-t of single dose
Time Frame: At the end of Cycle 1 (each cycle is 28 days)
|
At the end of Cycle 1 (each cycle is 28 days)
|
|
AUC0-∞ of single dose
Time Frame: At the end of Cycle 1 (each cycle is 28 days)
|
At the end of Cycle 1 (each cycle is 28 days)
|
|
Tmax of single dose
Time Frame: At the end of Cycle 1 (each cycle is 28 days)
|
At the end of Cycle 1 (each cycle is 28 days)
|
|
t1/2z of single dose
Time Frame: At the end of Cycle 1 (each cycle is 28 days)
|
At the end of Cycle 1 (each cycle is 28 days)
|
|
Vz/F of single dose
Time Frame: At the end of Cycle 1 (each cycle is 28 days)
|
At the end of Cycle 1 (each cycle is 28 days)
|
|
CLz/F of single dose
Time Frame: At the end of Cycle 1 (each cycle is 28 days)
|
At the end of Cycle 1 (each cycle is 28 days)
|
|
λz of single dose
Time Frame: At the end of Cycle 1 (each cycle is 28 days)
|
At the end of Cycle 1 (each cycle is 28 days)
|
|
MRT0-t of single dose
Time Frame: At the end of Cycle 1 (each cycle is 28 days)
|
At the end of Cycle 1 (each cycle is 28 days)
|
|
Rac of AUC and Cmax of first 28 days of multiple doses
Time Frame: At the end of Cycle 1 (each cycle is 28 days)
|
At the end of Cycle 1 (each cycle is 28 days)
|
|
DF of AUC and Cmax of first 28 days of multiple doses
Time Frame: At the end of Cycle 1 (each cycle is 28 days)
|
At the end of Cycle 1 (each cycle is 28 days)
|
|
Css,max of first 28 days of multiple doses
Time Frame: At the end of Cycle 1 (each cycle is 28 days)
|
At the end of Cycle 1 (each cycle is 28 days)
|
|
Css,min of first 28 days of multiple doses
Time Frame: At the end of Cycle 1 (each cycle is 28 days)
|
At the end of Cycle 1 (each cycle is 28 days)
|
|
AUCss of first 28 days of multiple doses
Time Frame: At the end of Cycle 1 (each cycle is 28 days)
|
At the end of Cycle 1 (each cycle is 28 days)
|
|
Cav of first 28 days of multiple doses
Time Frame: At the end of Cycle 1 (each cycle is 28 days)
|
At the end of Cycle 1 (each cycle is 28 days)
|
|
Tss,max of first 28 days of multiple doses
Time Frame: At the end of Cycle 1 (each cycle is 28 days)
|
At the end of Cycle 1 (each cycle is 28 days)
|
|
t1/2 of first 28 days of multiple doses
Time Frame: At the end of Cycle 1 (each cycle is 28 days)
|
At the end of Cycle 1 (each cycle is 28 days)
|
|
Vz/F of first 28 days of multiple doses
Time Frame: At the end of Cycle 1 (each cycle is 28 days)
|
、Vz/F、CLss/F、λz of first 28 days of multiple doses.
|
At the end of Cycle 1 (each cycle is 28 days)
|
CLss/F of first 28 days of multiple doses
Time Frame: At the end of Cycle 1 (each cycle is 28 days)
|
At the end of Cycle 1 (each cycle is 28 days)
|
|
λz of first 28 days of multiple doses
Time Frame: At the end of Cycle 1 (each cycle is 28 days)
|
At the end of Cycle 1 (each cycle is 28 days)
|
|
Objective response rate (ORR)
Time Frame: through study completion, an average of 1 year
|
ORR is defined as the proportion of subjects with confirmed CRc or PR.
|
through study completion, an average of 1 year
|
Composite response (CRc) rate
Time Frame: through study completion, an average of 1 year
|
CRc rate is defined as the proportion of subjects with confirmed CR or CRi or CRh.
|
through study completion, an average of 1 year
|
Duration of response (DOR)
Time Frame: through study completion, an average of 1 year
|
DOR is defined as the duration from the date of the first documented response of CR or PR to the date of the first documented recurrence or death.
|
through study completion, an average of 1 year
|
Recurrence-free survival (RFS)
Time Frame: through study completion, an average of 1 year
|
RFS is defined as the duration from the date of the first documented response of CRc to the date of the first documented recurrence or death.
|
through study completion, an average of 1 year
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NTQ2494-23101
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Relapsed/Refractory Acute Myeloid Leukemia (AML)
-
AvenCell Europe GmbHGCP-Service International Ltd. & Co. KGTerminatedAcute Myeloid Leukemia | Relapsed AML | Refractory AMLGermany
-
Elucida OncologyTherapeutic Advances in Childhood Leukemia and Lymphoma (TACL)WithdrawnAcute Myeloid Leukemia | AML, Childhood | Relapsed Pediatric AML | Refractory Pediatric AML
-
German Cancer Research CenterUniversity Hospital Heidelberg; University Hospital DresdenNot yet recruitingRelapsed/Refractory Acute Myeloid Leukemia (AML)Germany
-
Tarapeutics Science Inc.RecruitingRelapsed or Refractory Acute Myeloid Leukemia (AML)China
-
AstraZenecaTerminatedRelapsed or Refractory Acute Myeloid Leukemia (AML)United States
-
Tarapeutics Science Inc.RecruitingRelapsed or Refractory Acute Myeloid Leukemia (AML)China
-
New Epsilon Innovation LimitedActive, not recruitingAdvanced Solid Tumor | Relapsed AML | Refractory AMLHong Kong
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Not yet recruitingTreatment-naive or Relapsed or Refractory Acute Myeloid Leukemia (AML)China
-
French Innovative Leukemia OrganisationAcute Leukemia French AssociationRecruitingAML, Adult | Relapsed Adult AML | Refractory AML | FLT3-TKD Mutation | FLT3-ITDFrance
-
AmgenTerminatedRelapsed/Refractory Acute Myeloid Leukemia (AML)United States, Korea, Republic of, Australia, Japan, Germany, Canada
Clinical Trials on NTQ2494 tablet
-
Tasly Pharmaceutical Group Co., LtdCompleted
-
EstetraICON Clinical ResearchCompletedVasomotor Symptoms | Menopausal SymptomsUnited States, Canada
-
Sequel Pharmaceuticals, IncTerminatedAtrial Fibrillation
-
TakedaWithdrawn
-
Stallergenes GreerCompleted
-
Harmony Biosciences, LLCRecruiting
-
Xgene Pharmaceutical GroupRecruiting
-
Abbisko Therapeutics Co, LtdCompleted
-
Haisco Pharmaceutical Group Co., Ltd.Haisco Pharmaceutical(Australia) Pty Ltd.Completed
-
China Resources Sanjiu Medical & Pharmaceutical...Not yet recruitingAnkylosing SpondylitisChina